Annual Accounts Payable
$14.79 M
+$10.82 M+272.20%
31 December 2023
Summary:
Catalyst Pharmaceuticals annual accounts payable is currently $14.79 million, with the most recent change of +$10.82 million (+272.20%) on 31 December 2023. During the last 3 years, it has risen by +$10.54 million (+247.63%). CPRX annual accounts payable is now at all-time high.CPRX Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Accounts Payable
$11.56 M
+$4.45 M+62.49%
30 September 2024
Summary:
Catalyst Pharmaceuticals quarterly accounts payable is currently $11.56 million, with the most recent change of +$4.45 million (+62.49%) on 30 September 2024. Over the past year, it has increased by +$6.96 million (+151.48%). CPRX quarterly accounts payable is now -21.85% below its all-time high of $14.79 million, reached on 31 December 2023.CPRX Quarterly Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
CPRX Accounts Payable Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +272.2% | +151.5% |
| 3 y3 years | +247.6% | +320.2% |
| 5 y5 years | +533.0% | +178.8% |
CPRX Accounts Payable High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | at high | +434.5% | -21.9% | +399.5% |
| 5 y | 5 years | at high | +533.0% | -21.9% | +758.0% |
| alltime | all time | at high | >+9999.0% | -21.9% | >+9999.0% |
Catalyst Pharmaceuticals Accounts Payable History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $11.56 M(+62.5%) |
| June 2024 | - | $7.12 M(-30.7%) |
| Mar 2024 | - | $10.26 M(-30.6%) |
| Dec 2023 | $14.79 M(+272.2%) | $14.79 M(+221.8%) |
| Sept 2023 | - | $4.60 M(+4.0%) |
| June 2023 | - | $4.42 M(+30.4%) |
| Mar 2023 | - | $3.39 M(-14.7%) |
| Dec 2022 | $3.98 M(+43.6%) | $3.98 M(+57.2%) |
| Sept 2022 | - | $2.53 M(+9.2%) |
| June 2022 | - | $2.31 M(-55.0%) |
| Mar 2022 | - | $5.14 M(+85.7%) |
| Dec 2021 | $2.77 M(-35.0%) | $2.77 M(+0.6%) |
| Sept 2021 | - | $2.75 M(-5.9%) |
| June 2021 | - | $2.92 M(+14.2%) |
| Mar 2021 | - | $2.56 M(-39.8%) |
| Dec 2020 | $4.26 M(+3.4%) | $4.26 M(+112.2%) |
| Sept 2020 | - | $2.01 M(-65.5%) |
| June 2020 | - | $5.80 M(+330.8%) |
| Mar 2020 | - | $1.35 M(-67.3%) |
| Dec 2019 | $4.12 M(+76.2%) | $4.12 M(-0.7%) |
| Sept 2019 | - | $4.15 M(+24.6%) |
| June 2019 | - | $3.33 M(+13.2%) |
| Mar 2019 | - | $2.94 M(+25.8%) |
| Dec 2018 | $2.34 M(+20.1%) | $2.34 M(+74.3%) |
| Sept 2018 | - | $1.34 M(+45.4%) |
| June 2018 | - | $922.60 K(+14.6%) |
| Mar 2018 | - | $805.00 K(-58.6%) |
| Dec 2017 | $1.95 M(+108.5%) | $1.95 M(+79.9%) |
| Sept 2017 | - | $1.08 M(+56.2%) |
| June 2017 | - | $692.30 K(-24.6%) |
| Mar 2017 | - | $917.90 K(-1.6%) |
| Dec 2016 | $933.20 K(-48.0%) | $933.20 K(-11.6%) |
| Sept 2016 | - | $1.06 M(+49.2%) |
| June 2016 | - | $707.30 K(-43.5%) |
| Mar 2016 | - | $1.25 M(-30.2%) |
| Dec 2015 | $1.79 M | $1.79 M(+119.6%) |
| Sept 2015 | - | $817.00 K(-37.9%) |
| June 2015 | - | $1.32 M(+25.3%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2015 | - | $1.05 M(-42.1%) |
| Dec 2014 | $1.81 M(+113.2%) | $1.81 M(+245.7%) |
| Sept 2014 | - | $524.80 K(-57.6%) |
| June 2014 | - | $1.24 M(+32.8%) |
| Mar 2014 | - | $932.10 K(+9.6%) |
| Dec 2013 | $850.80 K(-37.7%) | $850.80 K(-42.3%) |
| Sept 2013 | - | $1.47 M(+228.6%) |
| June 2013 | - | $448.30 K(-21.0%) |
| Mar 2013 | - | $567.20 K(-58.5%) |
| Dec 2012 | $1.37 M(+417.5%) | $1.37 M(+283.7%) |
| Sept 2012 | - | $355.90 K(+59.6%) |
| June 2012 | - | $223.00 K(-36.3%) |
| Mar 2012 | - | $350.30 K(+32.7%) |
| Dec 2011 | $263.90 K(+149.2%) | $263.90 K(+51.7%) |
| Sept 2011 | - | $174.00 K(-63.6%) |
| June 2011 | - | $478.00 K(+12.4%) |
| Mar 2011 | - | $425.40 K(+301.7%) |
| Dec 2010 | $105.90 K(-57.6%) | $105.90 K(-56.1%) |
| Sept 2010 | - | $241.30 K(-4.2%) |
| June 2010 | - | $252.00 K(+185.4%) |
| Mar 2010 | - | $88.30 K(-64.6%) |
| Dec 2009 | $249.60 K(-25.0%) | $249.60 K(+53.0%) |
| Sept 2009 | - | $163.10 K(-40.8%) |
| June 2009 | - | $275.70 K(-62.6%) |
| Mar 2009 | - | $737.60 K(+121.7%) |
| Dec 2008 | $332.70 K(+51.3%) | $332.70 K(-47.7%) |
| Sept 2008 | - | $635.60 K(+250.6%) |
| June 2008 | - | $181.30 K(-42.7%) |
| Mar 2008 | - | $316.60 K(+44.0%) |
| Dec 2007 | $219.90 K(-50.9%) | $219.90 K(-4.2%) |
| Sept 2007 | - | $229.50 K(+56.8%) |
| June 2007 | - | $146.40 K(-53.2%) |
| Mar 2007 | - | $312.50 K(-30.3%) |
| Dec 2006 | $448.10 K(+560.9%) | $448.10 K(+7.3%) |
| Sept 2006 | - | $417.80 K(+1577.9%) |
| June 2006 | - | $24.90 K(-63.3%) |
| Dec 2005 | $67.80 K(+120.8%) | $67.80 K(+120.8%) |
| Dec 2004 | $30.70 K | $30.70 K |
FAQ
- What is Catalyst Pharmaceuticals annual accounts payable?
- What is the all time high annual accounts payable for Catalyst Pharmaceuticals?
- What is Catalyst Pharmaceuticals annual accounts payable year-on-year change?
- What is Catalyst Pharmaceuticals quarterly accounts payable?
- What is the all time high quarterly accounts payable for Catalyst Pharmaceuticals?
- What is Catalyst Pharmaceuticals quarterly accounts payable year-on-year change?
What is Catalyst Pharmaceuticals annual accounts payable?
The current annual accounts payable of CPRX is $14.79 M
What is the all time high annual accounts payable for Catalyst Pharmaceuticals?
Catalyst Pharmaceuticals all-time high annual accounts payable is $14.79 M
What is Catalyst Pharmaceuticals annual accounts payable year-on-year change?
Over the past year, CPRX annual accounts payable has changed by +$10.82 M (+272.20%)
What is Catalyst Pharmaceuticals quarterly accounts payable?
The current quarterly accounts payable of CPRX is $11.56 M
What is the all time high quarterly accounts payable for Catalyst Pharmaceuticals?
Catalyst Pharmaceuticals all-time high quarterly accounts payable is $14.79 M
What is Catalyst Pharmaceuticals quarterly accounts payable year-on-year change?
Over the past year, CPRX quarterly accounts payable has changed by +$6.96 M (+151.48%)